US FDA Now Assessing UDI Compliance When Inspecting Device Firms
This article was originally published in Clinica
Unique device identification (UDI) activities are now being reviewed by US Food and Drug Administration investigators during medical device facility inspections, an agency official says. In addition, firms that aren't required yet to abide by the UDI regulation will be quizzed about their preparedness.
You may also be interested in...
Manufacturers Scramble To Meet Looming Unique Device Identification Deadline – But Too Many Are Unprepared
US FDA and device industry experts are concerned that too many firms are woefully unprepared for, and undereducated about, the agency's Unique Device Identification program. A recent industry survey appears to bear this out: A whopping 85% of respondents say they're not ready for the upcoming UDI compliance deadline of Sept. 24 for makers of class II products. Meanwhile, firms asking for UDI exceptions for their devices are waiting an inordinate amount of time for FDA to come to a decision, in part because the agency simply doesn't know how to publicly disclose the exemptions, UDI guru Jay Crowley says. Also: experts mull over the agency's latest UDI guidance; FDA explains why using an HL7 UDI submission option for its GUDID database isn't a good idea for every firm; and Crowley discusses what the UDI landscape will look like in 2020.
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.